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Abstract
Background: A major problem in pain medicine is the lack of knowledge about which treatment suits a specific patient. We
tested the ability of quantitative sensory testing to predict the analgesic effect of pregabalin and placebo in patients with
chronic pancreatitis.
Methods: Sixty-four patients with painful chronic pancreatitis received pregabalin (150–300 mg BID) or matching placebo
for three consecutive weeks. Analgesic effect was documented in a pain diary based on a visual analogue scale. Responders
were defined as patients with a reduction in clinical pain score of 30% or more after three weeks of study treatment
compared to baseline recordings. Prior to study medication, pain thresholds to electric skin and pressure stimulation were
measured in dermatomes T10 (pancreatic area) and C5 (control area). To eliminate inter-subject differences in absolute pain
thresholds an index of sensitivity between stimulation areas was determined (ratio of pain detection thresholds in
pancreatic versus control area, ePDT ratio). Pain modulation was recorded by a conditioned pain modulation paradigm. A
support vector machine was used to screen sensory parameters for their predictive power of pregabalin efficacy.
Results: The pregabalin responders group was hypersensitive to electric tetanic stimulation of the pancreatic area (ePDT
ratio 1.2 (0.9–1.3)) compared to non-responders group (ePDT ratio: 1.6 (1.5–2.0)) (P= 0.001). The electrical pain detection
ratio was predictive for pregabalin effect with a classification accuracy of 83.9% (P= 0.007). The corresponding sensitivity
was 87.5% and specificity was 80.0%. No other parameters were predictive of pregabalin or placebo efficacy.
Conclusions: The present study provides first evidence that quantitative sensory testing predicts the analgesic effect of
pregabalin in patients with painful chronic pancreatitis. The method can be used to tailor pain medication based on
patient’s individual sensory profile and thus comprises a significant step towards personalized pain medicine.
Citation: Olesen SS, Graversen C, Bouwense SAW, van Goor H, Wilder-Smith OHG, et al. (2013) Quantitative Sensory Testing Predicts Pregabalin Efficacy in Painful
Chronic Pancreatitis. PLoS ONE 8(3): e57963. doi:10.1371/journal.pone.0057963
Editor: Christine Miaskowski, University of California, United States of America
Received October 18, 2012; Accepted January 29, 2013; Published March 1, 2013
Copyright:  2013 Olesen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by a free grant from Pfizer Research and Development and the Danish Agency for Science, Technology and Innovation:
Det Strategiske Forskningsra˚d; grant No.10-092786. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have the following interests. This research was partly supported by a free grant from Pfizer Research and Development. The
study was investigator initiated and Pfizer donated capsules of pregabalin and matching placebo. There are no further patents, products in development or
marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the
guide for authors.
* E-mail: sso@mech-sense.com
Introduction
A major problem for pain treatment is the lack of knowledge
about which treatment best suits a specific patient. This is
particularly important in patients with chronic pancreatitis (CP)
due to complex and multifactorial pain aetiology, involving many
factors including structural abnormalities of the pancreatic gland
as well as abnormalities of peripheral and central pain processing
[1]. Chronic pain in CP is also associated with malnutrition,
narcotic addiction, physical and emotional disability and major
socioeconomic problems, which further complicates and blurs the
clinical evaluation of treatment outcome [2,3]. For these reasons
pain management in CP is challenging and often leads to a time-
consuming and unsatisfactory approach to treatment with an
unpredictable outcome.
The complex pain aetiology and wide variability in group
treatment outcome makes it important to identify biomarkers
linked to outcomes of pain treatment in individual patients.
Quantitative sensory testing (QST) has in some studies been
able to predict treatment outcome of analgesic therapy in
chronic pain disorders [4–6]. It provides information on sensory
function at the peripheral and central level of the nervous
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system by recording the subjects’ responses to different external
stimuli of controlled intensity [7]. In painful CP, changes in
pain processing affect second order neurones in the central
nervous system (CNS) receiving convergent visceral and somatic
afferent information. Hence, sensory information from static
QST of skin dermatomes in the upper abdominal area can
indirectly be used to obtain information about CNS neuroplas-
ticity following increased barrage from pancreatic sensory
afferents [8,9]. In addition, QST can be used to gain
information on the dynamic function of the sensory system,
including descending inhibitory and facilitatory influences from
the brain stem and higher cortical levels, e.g. by using
conditioned pain modulation (CPM) paradigms [10].
A recent randomised, placebo controlled, clinical trial of
pregabalin in patients with painful CP provided the opportunity
to test a putative link between pre-treatment QST measure-
ments and effectiveness of pregabalin and placebo in treating
the pain of CP [11]. Pregabalin has effectively been used to
treat various chronic pain disorders, including diabetic neurop-
athy [12], post herpetic neuralgia [13], and neuropathic pain of
central origin [14]. It binds selectively to voltage dependent
calcium channels and blocks influx of calcium into presynaptic
nerve terminals [15]. This reduces release of excitatory
neurotransmitters on spinal neurons, and in turn reduces
neuronal excitability and upstream transmission in the central
nervous system [16].
We hypothesized pregabalin to be more efficacious in CP
patients characterized by central sensitization, as expressed by
increased responsiveness to static QST in the upper abdominal
region. In turn, we expected that descending pain modulation (i.e.
dynamic QST) would not be associated with pregabalin efficacy,
as pregabalin do not exert its primary effect through descending
pain modulation [17]. The aim of this study was to test this
hypothesis by testing the ability of static and dynamic QST to
predict pregabalin and placebo efficacy in patients with painful
CP.
Methods
Study Patients
Patients were recruited from an investigator initiated double-
blinded, placebo-controlled, parallel-group study of pregabalin for
painful CP conducted in Denmark (Department of Gastroenter-
ology and Hepatology, Aalborg Hospital, Aarhus University
Hospital) and the Netherlands (Department of Surgery, Radboud
University Nijmegen Medical Center) [11]. The present study
investigates the link between baseline QST measurements and
analgesic efficacy of pregabalin or placebo.
Key inclusion criteria were a diagnosis of CP based on The
Mayo Clinic Diagnostic Criteria and chronic abdominal pain
typical for pancreatitis, meeting the criteria for chronic pain
(pain $3 days per week in at least 3 months) and by the patient
considered severe enough for medical treatment [18]. Patients
taking concomitant analgesic medication and expected to stay
on a stable regime during the trial were allowed to enter the
study. Patients were excluded from the study if they had
a painful condition other than CP or were previously operated
in the areas subjected to QST. Testing in females was not
standardized with regard to phase of the menstrual cycle
because all pancreatitis patients had amenorrhea or were
postmenopausal.
The responsible Ethical Committees in both countries approved
the study and all patients provided written informed consent prior
to investigation.
Study Design and Treatment
The study consisted of a 3-week period of pregabalin or placebo
treatment titrated to analgesic effect and tolerability. In each
patient, a QST session was performed before starting study
medication. The session consisted of static (pain thresholds to
pressure and electric tetanic stimulation) and dynamic QST
(conditioned pain modulation, CPM). A detailed patient history
was obtained to determine pain localization, intensity of ongoing
pain (assessed by a 0–10 visual analogue scale (VAS)), and use of
analgesics. Patients were then instructed and trained in VAS
ratings to determine pain thresholds and the CPM paradigm. A 30
minute pause allowed the pain system to re-establish baseline
conditions and was followed by the QST test session.
After QST testing patients received escalating doses of
pregabalin (300 to 600 mg/day) or matching placebo capsules
for three weeks. Daily dosages were split into two equivalent doses,
one administered in the morning and one in the evening. If
unacceptable side effects were experienced by the patient, a single
downward dose titration was allowed, after which the patient
remained on the final dosage during the remainder of the study
period. A minimum end dose of 300 mg/day was required;
otherwise the subject was withdrawn from the study.
Clinical Outcome
The clinical endpoint was the percentage change in daily average
pain intensity after three weeks of treatment compared to baseline.
The average daily pain scores (i.e. the average pain score for the last
24 hours) were collected by a pain diary based on a visual
analogue scale (VAS), where 0 = no pain and 10=worst pain
imaginable. The baseline pain score was calculated as the average
daily pain score during the week prior to randomization (i.e. no
study medication). The response to study medication was
calculated as the average daily pain score during the last week
of treatment. Responders to treatment (pregabalin or placebo)
were defined as patients with a reduction in clinical pain score of
30% or more after three weeks of treatment compared to baseline
recordings.
Quantitative Sensory Testing
Pressure and electric tetanic threshold
testing. Threshold testing took place using a standard temporal
test sequence, which has been described in detail previously [9,19].
Pressure pain thresholds were obtained for muscles overlying bone
by pressing a handheld electronic pressure algometer (Somedic
AB, Stockholm, Sweden). The probe had a surface area of 1 cm2
and the pressure was increased at a rate of 30 kPa/sec. The lower
neck (C5 dermatome) and the upper abdominal area (ventral Th10
dermatome) on the dominant body side were stimulated. The
upper abdominal area was chosen because dorsal horn neurons
receiving painful stimuli from this skin area also receive
nociceptive stimuli from the pancreas (i.e. pancreatic area). In
contrast, the lower neck area was chosen because the nociceptive
pathways from this area are separated from those coming from the
pancreas at both peripheral and spinal levels (i.e. control area). For
each stimulation site, pain detection thresholds were measured
(pPDT, stimulation just becomes painful).
Pain thresholds to electric constant current skin stimulation
(ePDT) (Digistim; Biometer A/S, Copenhagen, Denmark; tetanic
stimulation at 100 Hz, 0.2 ms square waves, self-adhesive
electrodes 3 cm apart) were measured on the same sites as for
pressure stimulation.
To obtain an index of sensitivity between stimulation areas (i.e.
pancreatic area vs. control area) the relation between thresholds
was determined as pPDT ratio (pPDT pancreas/pPDT control)
Prediction of Pregabalin Efficacy
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and ePDT ratio (ePDT pancreas/ePDT control). This eliminated
inter-subject differences in absolute pain thresholds and thereby
provided a measure of ‘‘pancreatic sensitivity’’.
Conditioned pain modulation (CPM). The CPM para-
digm was performed to test the ability of the patient to generate
descending inhibitory modulation. CPM is a clinically measurable
form of descending pain modulation, which can be induced
experimentally by a conditioning stimulus (e.g. the cold pressor
test) and quantified by applying a test-stimulation before and after
its induction [10].
Conditioning stimulus - the cold pressor task: The right hand was
immersed in cooled water (2.0uC60.3uC, continuously stirred by
a pump). The patients were told to remove the hand from the
water after 3 minutes of immersion - or earlier if the pain was
considered to be intolerable. The duration of cold pressor
stimulation was measured for each patient (cold pressor).
Test stimulus - somatic pressure stimulation: Pain tolerance thresholds
(pPTT, painfulness of stimulation just becomes intolerable) was
determined on the quadriceps muscle 5 cm proximal to the patella
(corresponding to the L4 dermatome) before the cold pressor task
and immediately after its completion. The same pressure
algometer as for the static QST paradigm was used. The CPM
effect was defined as the relative change (%) in pPTT.
Prediction Algorithm
The prediction algorithm was utilized by a support vector
machine (SVM) based on machine learning [20]. SVM is a binary
classifier, which separates data from two groups by an optimal
separating threshold as illustrated in figure 1. The SVM was
chosen since it has been used for prediction in other studies of
biological data, and furthermore has the advantage that the
objective threshold is calculated without any a priori assumptions of
the discriminative features [21,22].
The SVM was applied to discriminate responders and non-
responders. As prediction studies should be based on analysis of
individual patients rather than statistical analysis of differences
between study groups, the various QST measurements should be
tested independently. Hence, the SVM was first applied to screen
the following parameters for discriminative capacity by a leave-
one-out approach (figure 1): 1) pPDT pancreas, 2) pPDT control,
3) pPDT ratio, 4) ePDT pancreas, 5) ePDT control, 6) ePDT ratio,
7) cold pressor time, and 8) CPM effect.
After screening the parameters, the QST measurements
leading to the maximum discrimination of the responders and
non-responders were considered the optimal prediction model.
The model was then assessed with respect to statistical
significance to predict if a patient would respond to pregabalin
or placebo treatment based on baseline QST assessment.
Finally, the SVM was applied to calculate the optimal
separation between patients.
Statistical Analysis
All data are presented as medians with interquartile ranges
unless otherwise indicated. Demographics, clinical data, and
baseline QST measurements for responders and non-responders
were compared by Wilcoxon signed rank test, Mann-Whitney U
test and Fisher’s exact test as appropriate. The significance of the
SVM discrimination between responders and non-responders was
analyzed by a Fisher’s exact test. A P-value ,0.05 was considered
as an indication of statistical significance. In case of multiple
Figure 1. Schematic illustration of the screening procedure with the support vector machine (SVM). The basic principle of the SVM is to
calculate a threshold which optimally discriminates responders and non-responders. The system performance is calculated by a leave-one-out
strategy (LOU) for each of the quantitative sensory testing (QST) parameters. The LOU strategy is a cross-validation procedure where the system tests
each patient individually by training the system on all other patients. Hence, the patient under test has not contributed to define the threshold. After
testing each of the patients, the system performance is calculated as the number of correctly classified patient out of the total number of patients,
which reflects the predictive capacity of the QST parameter.
doi:10.1371/journal.pone.0057963.g001
Table 1. Baseline demographic and clinical characteristics.
Pregabalin Placebo
Responders (n=16) Non-responders (n=15) Responders (n =12) Non-responders (n =17)
Age (years) 52 (50–59) 49 (43–57) 54 (41–63) 59 (49–64)
Males - no. (%) 9 (56) 8 (53) 9 (75) 10 (59)
Aetiology - no. (%) Toxic (alcohol) 6 (38) 9 (60) 9 (75) 7 (41)
Other 10 (63) 6 (40) 3 (25) 10 (59)
Diary pain score (VAS 0–10) 3.6 (2.6–5.1) 4.3 (2.4–6.5) 3.6 (2.1–5.1) 4.4 (2.1–5.0)
Concomitant analgesics – no. (%){ None 2 (13) 1 (7) 2 (17) 0 (0)
Weak analgesics 4 (25) 3 (20) 3 (25) 8 (47)
Strong analgesics 10 (63) 11 (73) 7 (58) 9 (53)
Opioid equipotency (mg/day) 71 (4–127) 80 (10–180) 45 (23–135) 48 (8–120)
Duration of CP (months) 83 (54–131) 117 (100–166 151 (77–212 84 (73–112)
Diabetes mellitus - no. (%) 7 (44) 3 (20) 6 (50) 4 (24)
EPI – no. (%) 7 (44) 6 (40) 6 (50) 9 (53)
Body mass index (kg/m2) 22(20–28) 19 (18–23) 22 (19–24) 22 (20–25)
Percentages may not total 100 due to rounding. VAS: visual analogue scale. CP: Chronic pancreatitis. EPI: exocrine pancreatic insufficiency.
{Weak analgesics were defined as non-steroid anti-inflammatory drugs, paracetamole, codeine and tramadole. Strong analgesics were defined as opioid based
therapies.
doi:10.1371/journal.pone.0057963.t001
Prediction of Pregabalin Efficacy
PLOS ONE | www.plosone.org 4 March 2013 | Volume 8 | Issue 3 | e57963
comparisons the P-value was adjusted to ,0.01 [23,24]. The
software package STATA version 11.2 (StataCorp LP, College
Station, Texas, USA) was used for statistical calculations.
Results
Sixty-four patients with painful CP were enrolled for the study
(i.e. randomized to receive pregabalin or placebo in the original
RCT [11]). Three patients in the pregabalin group and one
patient in the placebo group had incomplete pain diary data at
follow up and could not be classified as responders or non-
responders. Consequently, these subjects were excluded from the
further per-protocol analysis (n = 60). Clinical and demographic
characteristics of patients with stratification of data for responders
and non-responders are provided in Table 1. Groups were
balanced with respect to clinical and demographic pre-treatment
characteristics (all P.0.10).
Response to Pregabalin and Placebo Treatment
In the pregabalin group 16 of 31 patients (52%) were classified
as responders compared to 12 of 29 patients (42%) in the placebo
group (P= 0.45). A detailed analysis of the clinical endpoints was
reported previously [11].
Baseline QST Measurements
Baseline QST measurements are reported in Table 2 for the
pregabalin group and Table 3 for the placebo group. The
pregabalin responders group was hypersensitive to electric tetanic
stimulation of the pancreatic area (ePDT ratio: 1.2 (0.9–1.3))
compared to non-responders group (ePDT ratio: 1.6 (1.5–2.0))
(P=0.001). All other baseline QST measurements were compa-
rable between responders and non-responders (Table 2 and
Table 3).
Prediction of Pregabalin Effect
First, the different QST parameters in the pregabalin group
were screened by the leave-one-out approach. The ePDT ratio
was found to have the highest discriminatory power to separate
responders from non-responders (Figure 2). The classification
accuracy for this parameter was 80.6%, which was above chance
level compared to random performance (P=0.02). None of the
other baseline QST measurements reached classification accuracy
above chance level (Figure 2).
Next, data from all patients were used to train the SVM to
determine the optimal ePDT ratio to separate responders from
non-responders. The highest performance was found for an ePDT
ratio of 1.41, with a corresponding classification accuracy of
83.9% (P=0.007). For this threshold 14 of 16 patients were
correctly classified in the responders group and 12 of 15 patients
were correctly classified in the non-responders group (Figure 3).
These numbers correspond to a sensitivity of 87.5% and
a specificity of 80.0%. In figure 4 a simplified illustration of the
experimental setup and findings is provided.
Table 2. Baseline quantitative sensory testing measurements for the pregabalin treated group (n = 31).
All patients (n=31) Responders (n=16) Non-responders (n =15) P-value*
pPDT (kPa) Pancreatic area 155 (97–301) 155 (105–308) 146 (67–301) 0.37
Control area 263 (142–329) 269 (213–329) 175 (120–329) 0.38
pPDT ratio Pancreatic vs. control area 0.7 (0.5–1.0) 0.7 (0.5–1.0) 0.7 (0.6–1.0) 0.93
ePDT (mA) Pancreatic area 5.1 (3.3–8.1) 4.7 (2.8–6.2) 6.8 (4.2–10.4) 0.06
Control area 3.2 (2.3–5.1) 3.7 (2.7–5.1) 2.7 (2.2–5.6) 0.41
ePDT ratio Pancreatic vs. control area 1.3 (1.0–1.8) 1.2 (0.9–1.3) 1.6 (1.5–2.0) 0.001{
CPM (%) 2 (210–17) 4 (217–19) 0 (0–4) 0.63
Cold pressor (sec) 38 (23–57) 27 (18–56) 43 (25–57) 0.24
*Responders vs. non-responders.
{Significant result after adjustment for multiple comparisons. pPDT, pressure pain detection threshold; ePDT, electric tetanic pain detection threshold; CPM, conditioned
pain modulation.
doi:10.1371/journal.pone.0057963.t002
Table 3. Baseline quantitative sensory testing measurements for the placebo treated group (n = 29).
All patients (n=29) Responders (n=17) Non-responders (n =12) P-value*
pPDT (kPa) Pancreatic area 159 (85–264) 243 (88–352) 143 (68–260) 0.29
Control area 211 (106–380) 338 (125–458) 132 (97–341) 0.08
pPDT ratio Pancreatic vs. control area 0.7 (0.5–0.9) 0.7 (0.5–0.8) 0.8 (0.4–1.3) 0.55
ePDT (mA) Pancreatic area 5.4 (3.5–6.8) 5.6 (4.6–7.2) 3.8 (3.2–6.5) 0.35
Control area 4.2 (2.4–5.9) 3.9 (2.9–5.0) 4.7 (2.0–6.2) 0.79
ePDT ratio Pancreatic vs. control area 1.3 (1.0–1.5) 1.3 (1.0–1.7) 1.3 (1.0–1.3) 0.31
CPM (%) 12 (0–32) 16 (2–34) 10 (0–30) 0.85
Cold pressor (sec) 33 (23–98) 88 (25–180) 29 (20–46) 0.16
*Responders vs. non-responders. pPDT, pressure pain detection threshold; ePDT, electric tetanic pain detection threshold; CPM, conditioned pain modulation.
doi:10.1371/journal.pone.0057963.t003
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Figure 2. Predictive power of baseline QST measurements. The SVM was used to screen baseline QST measurements for their predictive
power of analgesic response to pregabalin and placebo. Only the electrical pain detection tolerance (ePDT) ratio in the pregabalin treated group
reached classification accuracy (80.6%) above chance level (74.2%; dotted line). CPM, conditioned pain modulation. *P= 0.02.
doi:10.1371/journal.pone.0057963.g002
Figure 3. Electrical pain detection tolerance (ePDT) ratios for responders and non-responders in the pregabalin group. The optimal
ratio to separate responder from non-responders was 1.41 (dotted line). This threshold separated groups with an accuracy of 83.9% (P= 0.007).
doi:10.1371/journal.pone.0057963.g003
Prediction of Pregabalin Efficacy
PLOS ONE | www.plosone.org 6 March 2013 | Volume 8 | Issue 3 | e57963
Prediction of Placebo Effect
A similar approach as for the pregabalin group was used to
screen QST parameters in the placebo group. The classification
accuracy for the ePDT ratio was 55.2%, which was not above
chance level compared to random performance (P=0.80). In
addition, none of the other baseline QST measurements in the
placebo group reached classification accuracy above chance level
(Figure 2).
Discussion
We investigated the link between pre-treatment QST measure-
ments and analgesic effect of pregabalin and placebo in patients
with painful CP. Pregabalin effect was associated with pre-
treatment sensitivity to electric tetanic QST. Hence, patients
expressing lower pain thresholds in the pancreatic viscerotome
compared to the control area are more likely to benefit from
pregabalin treatment, whereas those with no difference in pain
thresholds between the stimulation areas are less likely to benefit.
These findings suggest sensitization of spinal neurons in the
segment innervated by pancreatic visceral afferents to be an
important predictor of pregabalin efficacy in patients with painful
chronic pancreatitis. None of the QST parameters were associated
with placebo analgesia.
Methodological Considerations
Patients were instructed to report their daily average pain score
in a pain diary, but no instruction was given concerning timing of
daily pain score registration in relation to administration of study
medication. This could potentially influence registration of clinical
pain intensity. However, as pregabalin reach a steady state plasma
concentration after maximal 48 hours, the analgesic effect would
theoretically be constant throughout the day when administered
two times daily [25]. This is supported by a recent publication
where the pharmacokinetic profile of pregabalin was reported in
patient with CP and found to be comparable to that of healthy
subjects [26]. Also, patients were asked to report the average pain
score for the last 24 hours and not the pain score at the time of
registration. For these reasons we do not consider the timing of
pain score collection to be of major importance.
The reliability of QST measurements has previously been
reported in patients with CP [27]. Overall, sensory thresholds in
the pancreatic viscerotome and control area are reproducible over
time [27]. Conditioned pain modulation has been shown to be
reproducible in test retest experiments in healthy volunteers
[28,29]. In contrast, a recent study demonstrated considerable
variability of CPM in patients with CP [27]. Whether this
phenomenon is due to impaired descending modulation in CP
patients, as previously demonstrated in studies by our group,
remains unknown and need further investigation [30,31]. How-
ever, it may limit the usefulness of CPM for prediction of analgesic
potency in CP patients.
An index (ePDT ratio) reflecting the relation between stimula-
tion areas (i.e. pancreatic vs. control area) was derived to eliminate
individual differences in pain thresholds. The ratio reflects the
excitability of the neuronal pool with convergent projections from
pancreatic visceral afferents, thereby providing an indirect
measure of spinal neuronal excitability due to pancreatic
nociceptive input [8]. Whether increased responsiveness in the
pancreatic area reflected a true hyperalgesic state could not be
determined from the present study since a healthy control group
was not enrolled. However, several studies have documented
hyperalgesia, and sensitization of second order neurons receiving
convergent pancreatic input in patients with CP as compared to
healthy controls [9,30–32].
In order to obtain a clinical analogue to tonic pain and evoke
maximal conditioning effect, a temperature of 2.0uC was used for
the cold pressor paradigm [33]. Consequently, most subjects
removed their hand due to intolerable pain intensity (i.e. VAS 10).
For this reason, the cold pressor time was used for analysis instead
of the VAS score to avoid a ceiling effect in the data.
The method for CPM assessment was chosen based on
a previous review of the methodology of experimentally induced
pain modulation, where the most sensitive models reported an
average inhibitory effect of 40% [10]. In those studies the cold
pressor test to an upper extremity was used as conditioning stimuli,
in combination with mechanical stimulations of the lower body
(test stimulus). Similar modalities were chosen for the present
study, to obtain the widest possible dynamic range of CPM and to
ensure maximum heterotopy between testing and conditioning
stimulation.
Prediction of Pregabalin Efficacy
The rationale for the present study was based on the hypothesis
that analgesic agents used for CP should be prescribed by relating
their mode of action to the specific patient’s pattern of pain
processing. Thus, an agent targeting neuronal excitability, such as
pregabalin, should be more efficacious in patients with evidence of
neuronal sensitization. In agreement with this, we found that
Figure 4. A simplified illustration of the experimental setup
and findings. Increased afferent barrage from the pancreatic nerves
results in central nervous system hyperexcitability (black star) pre-
dominantly at the lower thoracic segments. Visceral and somatic nerves
converge on the same second order neurons and stimulation of the skin
in this ‘‘viscerotome’’ (Th10) is amplified and interpreted by the brain as
increased pain. Due to inter-individual differences in pain thresholds,
normalization of Th10 thresholds was employed using a stimulus of the
skin at C5 (control area) in the same subject. Pregabalin treated patients
with high degree of central hyperexcitability, expressed as the electrical
pain threshold ratio at Th10/C5 (ePDT ratio) ,1.4, responded in 14 of 16
cases (87.5%) of cases, whereas patients with less hyperexcitability
(higher ratio) responded in 3 of 15 cases (20%) (figure 3).
doi:10.1371/journal.pone.0057963.g004
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patients with segmental hyperalgesia of the pancreatic viscero-
tome, sharing spinal segmental innervation with the pancreas, had
a superior clinical response to pregabalin treatment compared to
patients with less pronounced hyperalgesia. This finding reflects
the known mechanisms of action underlying pregabalin analgesia.
Accordingly, in vitro studies indicate that pregabalin binds selec-
tively to the alpha-2-delta subunit of voltage dependent calcium
channels, thereby blocking the influx of calcium into presynaptic
nerve terminals [15]. This in turn reduces release of excitatory
neurotransmitters including glutamate, noradrenalin and sub-
stance P on spinal second order neurons, and thus dampens
neuronal excitability [34]. In agreement with this, clinical studies
have documented pregabalin’s analgesic efficacy in chronic pain
disorders characterized by neuronal sensitization, including pain-
ful CP [11–14,16]. In a recent trial we found this anti-nociceptive
effect to be mediated primarily through sub-cortical mechanisms
(i.e. spinal) [17]. This translates well to the findings of the present
study where segmental hyperalgesia of the pancreatic viscerotome
(reflecting spinal sensitization) was found to be associated with
pregabalin efficacy.
Only electric stimulation was predictive of pregabalin efficacy,
while pressure stimulation was not associated with clinical
outcome. This finding is in line with a recent study from our
group were pregabalin treatment resulted in a greater increase of
electric pain thresholds than of pressure pain thresholds [31]. A
possible explanation is that pregabalin is initially more effective in
reducing skin sensitization, as reflected by electric thresholds, as
compared to deep tissue sensitization, as reflected by pressure
thresholds [35]. Pressure stimulations using the algometer
potentially activate nociceptors in both the skin and in underlying
muscle or bone. However, it has been shown that anesthetizing the
skin will only result in minor changes in pressure thresholds and
we consider the stimulus to predominantly reflect pain in deep
structures [36].
Dynamic pain modulation (CPM) was not associated with
pregabalin efficacy, which is an expected finding since pregabalin
is not believed to target descending inhibitory pain modulation.
Furthermore, as discussed above, CPM is not stable over time in
CP patients, which may limit its usefulness for prediction of
analgesic potency in CP patients [27,30].
Clinical Implications
The experimental protocol presented in the current study
provides a non-invasive technique to identify patients with
a specific pattern of abnormalities in central pain processing. This
approach can be used to support clinicians when establishing
treatment indications in patients with pancreatic pain (or other
chronic pain disorders). Most analgesics are only effective in
a subset of patients and many have adverse effects [37]. The
mechanism-based approach presented here may thus help to
prevent a long and often painful trial and error process of finding
an appropriate therapy for the individual patient. Of particular
interest, preoperative evaluation of central pain processing could
also be a useful biomarker to identify those CP patients who will
not benefit from endoscopic or surgical interventions. Hence,
patients with evidence of severe central sensitization may have
a lower chance of successful outcome to surgery or endotherapy
compared to patients with less sensitization [19].
Conclusions
The present study provides first evidence that QST predicts the
analgesic efficacy of pregabalin in patients with painful CP. The
method thus carries the potential for shortening a long and painful
trial and error process of finding an appropriate therapy for the
individual patient and thus comprises a significant step towards
personalized pain medicine.
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